Mumbai, Aug 14 (IANS) Glenmark Pharmaceuticals on Wednesday reported a more than two-fold jump in its net profit to Rs 462 crore for the April-June quarter of the current financial year compared to the corresponding figure of Rs 203 crore in the same quarter of the previous year.
The increase in profit came on the back of a strong demand for the company’s medicines, while there was a marginal decline of 1.4 per cent in costs as well.
The Mumbai-headquartered pharma major’s revenue from operations rose 8 per cent to Rs 3,244 crore, while expenses declined 1.4 per cent.
The company had a one-time charge of Rs 52 crore in the first quarter of last year, carrying out repairs at its manufacturing facilities in India and the US.
Glenmark had announced on July 17 this year that it has received final approval from the US Food & Drug Administration (US FDA) to sell its generic drug Topiramate Capsules USP, 15 mg and 25 mg in the US market.
Glenmark’s Topiramate Capsules USP, 15 mg and 25 mg have been determined by the FDA to be bioequivalent and therapeutically equivalent1 to Topamax Capsules, 15 mg and 25 mg of Janssen Pharmaceuticals, Inc., and will be distributed in the US by Glenmark Pharmaceuticals Inc., USA, the company said.
According to IQVIATM sales data for the 12-month period ending May 2024, the Topamax Capsules, 15 mg and 25 mg market achieved annual sales of approximately $21.9 million, it added.
Glenmark said its current portfolio consists of 198 products authorised for distribution in the US marketplace and 50 ANDA’s pending approval with the US FDA.
An abbreviated new drug application (ANDA) contains data which is submitted to the FDA for the review and potential approval of a generic drug product.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments, with a focus on therapeutic areas of respiratory, dermatology and oncology.
The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries, according to information posted on its website.
–IANS
sps/pgh
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
